Influenza Vaccine Market

Influenza Vaccine Market (Type: Inactivated and Live Attenuated; Valency: Quadrivalent and Trivalent; Age Group: Pediatric and Adult) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2023-2031

Influenza Vaccine Market Outlook 2031

  • The global industry was valued at US$ 4.0 Bn in 2022
  • It is projected to grow at a CAGR of 7.2% from 2022 to 2031 and reach more than US$ 7.2 Bn by 2031

Analysts’ Viewpoint

The global influenza vaccine market is expected to grow at a rapid pace in the next few years. This can be ascribed to surge in prevalence of flu, rise in awareness, increase in geriatric population, and government initiatives to promote vaccination. Surge in number of collaborations between market players and governments to ensure availability of flu vaccines, such as swine flu vaccine, in remote areas is expected accelerate market development.

Introduction of new vaccines and increase in adoption in developing and underdeveloped countries offer significant opportunities to market players. Key players are focusing on research and development of innovative influenza vaccines. However, volatility in prices of raw materials used in the manufacture of vaccines, high cost of flu vaccines, and limited awareness and access in developing countries are expected to hamper market progress.

Influenza Vaccine Market

Influenza Vaccine Market Introduction

Influenza vaccine, also known as flu shot, is a crucial tool in preventing and controlling the spread of the influenza virus. The flu virus is highly contagious and could cause severe symptoms such as fever, cough, body ache, and fatigue. Influenza vaccines are available in various forms, including the traditional injected vaccine and nasal spray vaccines. Injected vaccine contains inactivated or weakened strains of the flu virus, while nasal spray vaccine contains live but weakened strains of the virus. Both types of vaccine trigger the body's immune system to produce an immune response, which helps protect against future infections.

Influenza vaccines are recommended for everyone over the age of six months, especially for people who are at high risk of developing serious complications from the flu, such as the elderly, young children, pregnant women, and people with weakened immune systems. However, influenza vaccines may not provide complete protection against the flu, and the level of protection could vary depending on factors such as age, health status, and the match between the vaccine and the circulating flu strains. Despite these limitations, influenza vaccines are the most effective way to prevent and control the spread of the flu virus. Regular vaccination, combined with good hygiene practices, such as frequent hand washing and covering the mouth and nose while coughing or sneezing, could help prevent the spread of flu and reduce the risk of serious complications.

Advances in Healthcare Infrastructure and Introduction of New Vaccine Products

Development of robust healthcare infrastructure and introduction of new flu vaccine products are driving global influenza vaccine market growth. Increase in availability of vaccines and expansion of healthcare systems in developing countries are making it easier for people to access these lifesaving products. For instance, in 2021, several major pharmaceutical companies, such as Pfizer and Moderna, announced the launch of new, highly effective influenza vaccines that offer improved protection against a wider range of flu strains. These new vaccines are expected to bolster market development.

Surge in number of collaborations between market players and governments to ensure the availability of flu vaccines in remote areas is propelling the market. For instance, in 2019, GlaxoSmithKline announced collaboration with the Bill and Melinda Gates Foundation to increase access to flu vaccines in low- and middle-income countries.

Adoption of Inactivated Vaccines for People at Higher Risk of Complications from Flu

In terms of type, the inactivated segment dominated the global influenza vaccine market in 2022. Inactivated influenza vaccine is an important tool in preventing and controlling the spread of the flu virus. These vaccines, which are made from dead strains of the flu virus, are the most commonly used form of flu vaccines and are considered safe and effective. One of the key advantages of inactivated influenza vaccines is high level of safety. Since the virus strains used in these vaccines are dead, these cannot cause a live flu infection. This makes inactivated vaccines an ideal option for people who are at higher risk of serious complications from the flu, such as pregnant women, people with weakened immune systems, and young children.

Rise in demand for flu vaccines and increase in awareness about the severity of influenza are propelling the inactivated segment. In 2021, the World Health Organization (WHO) launched a global public awareness campaign to encourage people to get vaccinated against influenza due to the COVID-19 pandemic.

Quadrivalent Vaccines Protect Against Four Strains of Flu Virus

Based on valency, the quadrivalent segment dominated the global market in 2022. Quadrivalent influenza vaccines offer better protection against the flu virus. One of the key advantages of quadrivalent vaccines is increased effectiveness in preventing the flu. Unlike traditional trivalent vaccines, which protect against three strains of the flu virus, quadrivalent vaccines protect against four strains. These vaccines are able to keep pace with rapidly evolving flu viruses and provide better protection. This is particularly important given the unpredictable nature of the flu virus and rapid rate at which it can evolve and change.

High Number of Influenza Vaccines for Adults

In terms of age group, the adult segment accounted for largest global influenza vaccine market share in 2022. The adult population is much larger than the younger population. According to the World Population Review of 2020, the population of adults aged 18 and above was around 4.6 billion, while the population of children aged 12 to 18 was nearly 1.2 billion. Moreover, the number of influenza vaccines for pediatrics is less than that for adults. For instance, the Pfizer-BioNTech vaccine was the first COVID-19 vaccine approved in the U.S., and it was only approved for people aged 16 and above. Thus, the adult population is more likely to get vaccinated than the younger population.

Availability of Influenza Vaccines in Hospitals and Pharmacies

Based on distribution channel, the hospitals & pharmacies segment dominated the global influenza vaccine market in 2022. This is ascribed to increase in availability of flu shot vaccines, expansion of healthcare infrastructure, rise in demand for flu vaccines, and convenience & accessibility. Hospitals and pharmacies are typically located within reach of the majority of the population, and these offer the convenience of walk-in appointments or scheduled visits. This makes them an ideal place for people to receive flu vaccine, particularly given the growing emphasis on preventative healthcare. Pharmacists are well-positioned to provide advice and guidance about the flu vaccine, as well as to administer the vaccine. As flu vaccination becomes increasingly important for preventing the spread of flu, hospital and pharmacy distribution channels are poised to play a crucial role in ensuring that people have access to the vaccines they need to protect themselves and their communities.

Regional Analysis of Global Influenza Vaccine Market

North America is one of the largest markets for influenza vaccines. The market in the region is driven by high incidence of flu and well-established healthcare infrastructure. The Centers for Disease Control and Prevention (CDC) recommends that everyone aged six months and older should receive a flu vaccine each year. Furthermore, increase in awareness about the importance of flu vaccination is propelling the influenza vaccine market in North America.

Asia Pacific is an emerging market for influenza vaccines. The market in the region is driven by growing burden of flu and improving healthcare infrastructure. The number of flu cases has increased in countries, such as India, China, and Australia, in the past few years, leading to rise in influenza vaccine market demand. Rise in awareness about the importance of flu vaccination and increase in availability of vaccines are accelerating market growth in Asia Pacific.

Analysis of Key Players

The influenza vaccine market report includes vital information about leading influenza vaccine manufacturers operating in the global market. Key players are adopting strategies such as product launches, divestiture, mergers & acquisitions (M&A), and partnerships to strengthen their position in the market. Pfizer, Inc., Sanofi, GlaxoSmithKline (GSK), AstraZeneca, Merck & Co., Inc., Novartis AG, Roche Holding AG, Seqirus (CSL Limited), Johnson & Johnson and Daiichi Sankyo Company, Limited are the prominent players operating in the market.

Key Developments

  • In February 2021, Pfizer and BioNTech announced the approval of COVID-19 vaccine for emergency use in the U.S. This approval marked a major milestone in the global fight against COVID-19, and demonstrated the ability of pharmaceutical companies to quickly develop and bring to market vaccines for emerging infectious diseases.

Key players in the market has been profiled in the report based on parameters such as company overview, financial overview, business strategies, product portfolio, business segments, and recent developments.

Global Influenza Vaccine Market Snapshot

Attribute Detail
Size in 2022 US$ 4.0 Bn
Forecast (Value) in 2031 More than US$ 7.2 Bn
Compound Annual Growth Rate (CAGR) 7.2%
Forecast Period 2023-2031
Historical Data Available for 2017-2022
Quantitative Units US$ Bn for Value
Market Analysis It includes segment analysis as well as regional level analysis. Moreover, qualitative analysis includes drivers, restraints, opportunities, key trends, and parent industry overview.
Competition Landscape
  • Market share analysis/ranking by company (2022)
  • Company profiles section includes overview, product portfolio, key subsidiaries or distributors, strategy & recent developments, and key financials
Format Electronic (PDF) + Excel
Market Segmentation
  • Type
    • Inactivated
    • Live Attenuated
  • Valency
    • Quadrivalent
    • Trivalent
  • Age Group
    • Pediatric
    • Adult
  • Distribution Channel
    • Hospitals & Pharmacies
    • Government & Institutional Supply
    • Others
Regions Covered
  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East & Africa
Countries Covered
  • U.S.
  • Canada
  • Germany
  • U.K.
  • France
  • Italy
  • Spain
  • China
  • India
  • Japan
  • Australia & New Zealand
  • Brazil
  • Mexico
  • GCC Countries
  • South Africa
Companies Profiled
  • Pfizer, Inc.
  • Sanofi
  • GlaxoSmithKline (GSK)
  • AstraZeneca
  • Merck & Co., Inc.
  • Novartis AG
  • Roche Holding AG
  • Seqirus (CSL Limited)
  • Johnson & Johnson
  • Daiichi Sankyo Company, Limited.
  • Sanofi-GSK
Customization Scope Available upon request
Pricing Available upon request

Frequently Asked Questions

How big was the global Influenza vaccine market in 2022?

The global market was valued at US$ 4.0 Bn in 2022

How big will it be by 2031?

It is projected to reach more than US$ 7.2 Bn by 2031

What will be the CAGR during the forecast period?

The CAGR is anticipated to be 7.2% from 2023 to 2031

Which are the prominent trends that affect growth?

Rise in awareness about influenza, improving healthcare infrastructure, and introduction of new vaccine products

Which segment accounted for major share?

The quadrivalent segment held the largest share in 2022

Which region will account for significant share?

North America is expected to account for leading share during the forecast period

Who are the prominent players in the global market?

Pfizer, Inc., Sanofi, GlaxoSmithKline (GSK), AstraZeneca, Merck & Co., Inc., Novartis AG, Roche Holding AG, Seqirus (CSL Limited), Johnson & Johnson, and Daiichi Sankyo Company, Limited

1. Preface

    1.1. Market Definition and Scope

    1.2. Market Segmentation

    1.3. Key Research Objectives

    1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary: Global Influenza Vaccine Market

4. Market Overview

    4.1. Introduction

        4.1.1. Type Definition

        4.1.2. Industry Evolution / Developments

    4.2. Overview

    4.3. Market Dynamics

        4.3.1. Drivers

        4.3.2. Restraints

        4.3.3. Opportunities

    4.4. Global Influenza Vaccine Market Analysis and Forecast, 2017-2031

5. Key Insights

    5.1. Reimbursement Scenario by Region/globally

    5.2. Diseases Incidence and prevalence

    5.3. Regulatory scenario in key region/Countries

    5.4. Covid-19 Impact on Industry

6. Global Influenza Vaccine Market Analysis and Forecast, by Type

    6.1. Introduction & Definition

    6.2. Key Findings / Developments

    6.3. Market Value Forecast, by Type, 2017-2031

        6.3.1. Inactivated

        6.3.2. Live Attenuated

    6.4. Market Attractiveness Analysis, by Type

7. Global Influenza Vaccine Market Analysis and Forecast, by Valency

    7.1. Introduction & Definition

    7.2. Key Findings / Developments

    7.3. Market Value Forecast, by Valency, 2017-2031

        7.3.1. Quadrivalent

        7.3.2. Trivalent

    7.4. Market Attractiveness Analysis, by Valency

8. Global Influenza Vaccine Market Analysis and Forecast, by Age Group

    8.1. Introduction & Definition

    8.2. Key Findings / Developments

    8.3. Market Value Forecast, by Age Group, 2017-2031

        8.3.1. Pediatric

        8.3.2. Adult

    8.4. Market Attractiveness Analysis, by Age Group

9. Global Influenza Vaccine Market Analysis and Forecast, by Distribution Channel

    9.1. Introduction & Definition

    9.2. Key Findings / Developments

    9.3. Market Value Forecast, by Distribution Channel, 2017-2031

        9.3.1. Hospitals & Pharmacies

        9.3.2. Government & Institutional Supply

        9.3.3. Others

    9.4. Market Attractiveness Analysis, by Distribution Channel

10. Global Influenza Vaccine Market Analysis and Forecast, by Region

    10.1. Key Findings

    10.2. Market Value Forecast, by Region

        10.2.1. North America

        10.2.2. Europe

        10.2.3. Asia Pacific

        10.2.4. Latin America

        10.2.5. Middle East & Africa

    10.3. Market Attractiveness Analysis, by Region

11. North America Influenza Vaccine Market Analysis and Forecast

    11.1. Introduction

        11.1.1. Key Findings

    11.2. Market Value Forecast, by Type, 2017-2031

        11.2.1. Inactivated

        11.2.2. Live Attenuated

    11.3. Market Value Forecast, by Valency, 2017-2031

        11.3.1. Quadrivalent

        11.3.2. Trivalent

    11.4. Market Value Forecast, by Age Group, 2017-2031

        11.4.1. Pediatric

        11.4.2. Adult

    11.5. Market Value Forecast, by Distribution Channel, 2017-2031

        11.5.1. Hospitals & Pharmacies

        11.5.2. Government & Institutional Supply

        11.5.3. Others

    11.6. Market Value Forecast, by Country, 2017-2031

        11.6.1. U.S.

        11.6.2. Canada

    11.7. Market Attractiveness Analysis

        11.7.1. By Type

        11.7.2. By Valency

        11.7.3. By Age Group

        11.7.4. By Distribution Channel

        11.7.5. By Country

12. Europe Influenza Vaccine Market Analysis and Forecast

    12.1. Introduction

        12.1.1. Key Findings

    12.2. Market Value Forecast, by Type, 2017-2031

        12.2.1. Inactivated

        12.2.2. Live Attenuated

    12.3. Market Value Forecast, by Valency, 2017-2031

        12.3.1. Quadrivalent

        12.3.2. Trivalent

    12.4. Market Value Forecast, by Age Group, 2017-2031

        12.4.1. Pediatric

        12.4.2. Adult

    12.5. Market Value Forecast, by Distribution Channel, 2017-2031

        12.5.1. Hospitals & Pharmacies

        12.5.2. Government & Institutional Supply

        12.5.3. Others

    12.6. Market Value Forecast, by Country/Sub-region, 2017-2031

        12.6.1. Germany

        12.6.2. U.K.

        12.6.3. France

        12.6.4. Spain

        12.6.5. Italy

        12.6.6. Rest of Europe

    12.7. Market Attractiveness Analysis

        12.7.1. By Type

        12.7.2. By Valency

        12.7.3. By Age Group

        12.7.4. By Distribution Channel

        12.7.5. By Country/Sub-region

13. Asia Pacific Influenza Vaccine Market Analysis and Forecast

    13.1. Introduction

        13.1.1. Key Findings

    13.2. Market Value Forecast, by Type, 2017-2031

        13.2.1. Inactivated

        13.2.2. Live Attenuated

    13.3. Market Value Forecast, by Valency, 2017-2031

        13.3.1. Quadrivalent

        13.3.2. Trivalent

    13.4. Market Value Forecast, by Age Group, 2017-2031

        13.4.1. Pediatric

        13.4.2. Adult

    13.5. Market Value Forecast, by Distribution Channel, 2017-2031

        13.5.1. Hospitals & Pharmacies

        13.5.2. Government & Institutional Supply

        13.5.3. Others

    13.6. Market Value Forecast, by Country/Sub-region, 2017-2031

        13.6.1. China

        13.6.2. Japan

        13.6.3. India

        13.6.4. Australia & New Zealand

        13.6.5. Rest of Asia Pacific

    13.7. Market Attractiveness Analysis

        13.7.1. By Type

        13.7.2. By Valency

        13.7.3. By Age Group

        13.7.4. By Distribution Channel

        13.7.5. By Country/Sub-region

14. Latin America Influenza Vaccine Market Analysis and Forecast

    14.1. Introduction

        14.1.1. Key Findings

    14.2. Market Value Forecast, by Type, 2017-2031

        14.2.1. Inactivated

        14.2.2. Live Attenuated

    14.3. Market Value Forecast, by Valency, 2017-2031

        14.3.1. Quadrivalent

        14.3.2. Trivalent

    14.4. Market Value Forecast, by Age Group, 2017-2031

        14.4.1. Pediatric

        14.4.2. Adult

    14.5. Market Value Forecast, by Distribution Channel, 2017-2031

        14.5.1. Hospitals & Pharmacies

        14.5.2. Government & Institutional Supply

        14.5.3. Others

    14.6. Market Value Forecast, by Country/Sub-region, 2017-2031

        14.6.1. Brazil

        14.6.2. Mexico

        14.6.3. Rest of Latin America

    14.7. Market Attractiveness Analysis

        14.7.1. By Type

        14.7.2. By Valency

        14.7.3. By Age Group

        14.7.4. By Distribution Channel

        14.7.5. By Country/Sub-region

15. Middle East & Africa Influenza Vaccine Market Analysis and Forecast

    15.1. Introduction

        15.1.1. Key Findings

    15.2. Market Value Forecast, by Type, 2017-2031

        15.2.1. Inactivated

        15.2.2. Live Attenuated

    15.3. Market Value Forecast, by Valency, 2017-2031

        15.3.1. Quadrivalent

        15.3.2. Trivalent

    15.4. Market Value Forecast, by Age Group, 2017-2031

        15.4.1. Pediatric

        15.4.2. Adult

    15.5. Market Value Forecast, by Distribution Channel, 2017-2031

        15.5.1. Hospitals & Pharmacies

        15.5.2. Government & Institutional Supply

        15.5.3. Others

    15.6. Market Value Forecast, by Country/Sub-region, 2017-2031

        15.6.1. GCC Countries

        15.6.2. South Africa

        15.6.3. Rest of Middle East & Africa

    15.7. Market Attractiveness Analysis

        15.7.1. By Type

        15.7.2. By Valency

        15.7.3. By Age Group

        15.7.4. By Distribution Channel

        15.7.5. By Country/Sub-region

16. Competition Landscape

    16.1. Market Player - Competition Matrix (by tier and size of companies)

    16.2. Market Share Analysis, by Company (2022)

    16.3. Company Profiles

        16.3.1. Pfizer, Inc.

            16.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)

            16.3.1.2. Type Portfolio

            16.3.1.3. Financial Overview

            16.3.1.4. SWOT Analysis

            16.3.1.5. Strategic Overview

        16.3.2. Sanofi

            16.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)

            16.3.2.2. Type Portfolio

            16.3.2.3. Financial Overview

            16.3.2.4. SWOT Analysis

            16.3.2.5. Strategic Overview

        16.3.3. GlaxoSmithKline (GSK)

            16.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)

            16.3.3.2. Type Portfolio

            16.3.3.3. Financial Overview

            16.3.3.4. SWOT Analysis

            16.3.3.5. Strategic Overview

        16.3.4. AstraZeneca

            16.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)

            16.3.4.2. Type Portfolio

            16.3.4.3. Financial Overview

            16.3.4.4. SWOT Analysis

            16.3.4.5. Strategic Overview

        16.3.5. Merck & Co., Inc.

            16.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)

            16.3.5.2. Type Portfolio

            16.3.5.3. Financial Overview

            16.3.5.4. SWOT Analysis

        16.3.6. Novartis AG

            16.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)

            16.3.6.2. Type Portfolio

            16.3.6.3. Financial Overview

            16.3.6.4. SWOT Analysis

        16.3.7. Roche Holding AG

            16.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)

            16.3.7.2. Type Portfolio

            16.3.7.3. Financial Overview

            16.3.7.4. SWOT Analysis

        16.3.8. Seqirus (CSL Limited)

            16.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)

            16.3.8.2. Type Portfolio

            16.3.8.3. Financial Overview

            16.3.8.4. SWOT Analysis

        16.3.9. Johnson & Johnson

            16.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)

            16.3.9.2. Type Portfolio

            16.3.9.3. Financial Overview

        16.3.10. Daiichi Sankyo Company, Limited

            16.3.10.1. Company Overview (HQ, Business Segments, Employee Strength)

            16.3.10.2. Type Portfolio

            16.3.10.3. Financial Overview

            16.3.10.4. SWOT Analysis

List of Tables

Table 01: Global Influenza Vaccine Market Value (US$ Mn) Forecast, by Type, 2017-2031

Table 02: Global Influenza Vaccine Market Value (US$ Mn) Forecast, by Age Group, 2017-2031

Table 03: Global Influenza Vaccine Market Value (US$ Mn) Forecast, by Valency, 2017-2031

Table 04: Global Influenza Vaccine Market Value (US$ Mn) Forecast, by Distribution Channel, 2017-2031

Table 05: Global Influenza Vaccine Market Value (US$ Mn) Forecast, by Region, 2017-2031

Table 06: North America Influenza Vaccine Market Value (US$ Mn) Forecast, by Country, 2017-2031

Table 07: North America Influenza Vaccine Market Value (US$ Mn) Forecast, by Type, 2017-2031

Table 08: North America Influenza Vaccine Market Value (US$ Mn) Forecast, by Age Group, 2017-2031

Table 09: North America Influenza Vaccine Market Value (US$ Mn) Forecast, by Valency, 2017-2031

Table 10: North America Influenza Vaccine Market Value (US$ Mn) Forecast, by Distribution Channel, 2017-2031

Table 11: Europe Influenza Vaccine Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031

Table 12: Europe Influenza Vaccine Market Value (US$ Mn) Forecast, by Type, 2017-2031

Table 13: Europe Influenza Vaccine Market Value (US$ Mn) Forecast, by Age Group, 2017-2031

Table 14: Europe Influenza Vaccine Market Value (US$ Mn) Forecast, by Valency, 2017-2031

Table 15: Europe Influenza Vaccine Market Value (US$ Mn) Forecast, by Distribution Channel, 2017-2031

Table 16: Asia Pacific Influenza Vaccine Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031

Table 17: Asia Pacific Influenza Vaccine Market Value (US$ Mn) Forecast, by Type, 2017-2031

Table 18: Asia Pacific Influenza Vaccine Market Value (US$ Mn) Forecast, by Age Group, 2017-2031

Table 19: Asia Pacific Influenza Vaccine Market Value (US$ Mn) Forecast, by Valency, 2017-2031

Table 20: Asia Pacific Influenza Vaccine Market Value (US$ Mn) Forecast, by Distribution Channel, 2017-2031

Table 21: Latin America Influenza Vaccine Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031

Table 22: Latin America Influenza Vaccine Market Value (US$ Mn) Forecast, by Type, 2017-2031

Table 23: Latin America Influenza Vaccine Market Value (US$ Mn) Forecast, by Age Group, 2017-2031

Table 24: Latin America Influenza Vaccine Market Value (US$ Mn) Forecast, by Valency, 2017-2031

Table 25: Latin America Influenza Vaccine Market Value (US$ Mn) Forecast, by Distribution Channel, 2017-2031

Table 26: Middle East & Africa Influenza Vaccine Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031

Table 27: Middle East & Africa Influenza Vaccine Market Value (US$ Mn) Forecast, by Type, 2017-2031

Table 28: Middle East & Africa Influenza Vaccine Market Value (US$ Mn) Forecast, by Age Group, 2017-2031

Table 29: Middle East & Africa Influenza Vaccine Market Value (US$ Mn) Forecast, by Valency, 2017-2031

Table 30: Middle East & Africa Influenza Vaccine Market Value (US$ Mn) Forecast, by Distribution Channel, 2017-2031

List of Figures

Figure 01: Global Influenza Vaccine Market Value (US$ Mn) Forecast, 2017-2031

Figure 02: Global Influenza Vaccine Market Value Share, by Type (2022)

Figure 03: Global Influenza Vaccine Market Value Share, by Valency (2022)

Figure 04: Global Influenza Vaccine Market Value Share, by Age Group (2022)

Figure 05: Global Influenza Vaccine Market Value Share, by Distribution Channel (2022)

Figure 06: Global Influenza Vaccine Market Value Share, by Region (2022)

Figure 07: Global Influenza Vaccine Market Value Share Analysis, by Type, 2022 and 2031

Figure 08: Global Influenza Vaccine Market Attractiveness Analysis, by Type, 2023-2031

Figure 09: Global Influenza Vaccine Market Value Share Analysis, by Age Group, 2022 and 2031

Figure 10: Global Influenza Vaccine Market Attractiveness Analysis, by Age Group, 2023-2031

Figure 11: Global Influenza Vaccine Market Value Share Analysis, by Valency, 2022 and 2031

Figure 12: Global Influenza Vaccine Market Attractiveness Analysis, by Valency, 2023-2031

Figure 13: Global Influenza Vaccine Market Value Share Analysis, by Distribution Channel, 2022 and 2031

Figure 14: Global Influenza Vaccine Market Attractiveness Analysis, by Distribution Channel, 2023-2031

Figure 15: Global Influenza Vaccine Market Value Share Analysis, by Region, 2022 and 2031

Figure 16: Global Influenza Vaccine Market Attractiveness Analysis, by Region, 2022-2031

Figure 17: North America Influenza Vaccine Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017-2031

Figure 18: North America Influenza Vaccine Market Value Share Analysis, by Country, 2022 and 2031

Figure 19: North America Influenza Vaccine Market Attractiveness Analysis, by Country, 2023-2031

Figure 20: North America Influenza Vaccine Market Value Share Analysis, by Type, 2022 and 2031

Figure 21: North America Influenza Vaccine Market Attractiveness Analysis, by Type, 2023-2031

Figure 22: North America Influenza Vaccine Market Value Share Analysis, by Age Group, 2022 and 2031

Figure 23: North America Influenza Vaccine Market Attractiveness Analysis, by Age Group, 2023-2031

Figure 24: North America Influenza Vaccine Market Value Share Analysis, by Valency, 2022 and 2031

Figure 25: North America Influenza Vaccine Market Attractiveness Analysis, by Valency, 2023-2031

Figure 26: North America Influenza Vaccine Market Value Share Analysis, by Distribution Channel, 2022 and 2031

Figure 27: North America Influenza Vaccine Market Attractiveness Analysis, by Distribution Channel, 2023-2031

Figure 28: Europe Influenza Vaccine Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017-2031

Figure 29: Europe Influenza Vaccine Market Value Share Analysis, by Country/Sub-region, 2022 and 2031

Figure 30: Europe Influenza Vaccine Market Attractiveness Analysis, by Country/Sub-region, 2023-2031

Figure 31: Europe Influenza Vaccine Market Value Share Analysis, by Type, 2022 and 2031

Figure 32: Europe Influenza Vaccine Market Attractiveness Analysis, by Type, 2023-2031

Figure 33: Europe Influenza Vaccine Market Value Share Analysis, by Age Group, 2022 and 2031

Figure 34: Europe Influenza Vaccine Market Attractiveness Analysis, by Age Group, 2023-2031

Figure 35: Europe Influenza Vaccine Market Value Share Analysis, by Valency, 2022 and 2031

Figure 36: Europe Influenza Vaccine Market Attractiveness Analysis, by Valency, 2023-2031

Figure 37: Europe Influenza Vaccine Market Value Share Analysis, by Distribution Channel, 2022 and 2031

Figure 38: Europe Influenza Vaccine Market Attractiveness Analysis, by Distribution Channel, 2023-2031

Figure 39: Asia Pacific Influenza Vaccine Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017-2031

Figure 40: Asia Pacific Influenza Vaccine Market Value Share Analysis, by Country/Sub-region, 2022 and 2031

Figure 41: Asia Pacific Influenza Vaccine Market Attractiveness Analysis, by Country/Sub-region, 2023-2031

Figure 42: Asia Pacific Influenza Vaccine Market Value Share Analysis, by Type, 2022 and 2031

Figure 43: Asia Pacific Influenza Vaccine Market Attractiveness Analysis, by Type, 2023-2031

Figure 44: Asia Pacific Influenza Vaccine Market Value Share Analysis, by Age Group, 2022 and 2031

Figure 45: Asia Pacific Influenza Vaccine Market Attractiveness Analysis, by Age Group, 2023-2031

Figure 46: Asia Pacific Influenza Vaccine Market Value Share Analysis, by Valency, 2022 and 2031

Figure 47: Asia Pacific Influenza Vaccine Market Attractiveness Analysis, by Valency, 2023-2031

Figure 48: Asia Pacific Influenza Vaccine Market Value Share Analysis, by Distribution Channel, 2022 and 2031

Figure 49: Asia Pacific Influenza Vaccine Market Attractiveness Analysis, by Distribution Channel, 2023-2031

Figure 50: Latin America Influenza Vaccine Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017-2031

Figure 51: Latin America Influenza Vaccine Market Value Share Analysis, by Country/Sub-region, 2022 and 2031

Figure 52: Latin America Influenza Vaccine Market Attractiveness Analysis, by Country/Sub-region, 2023-2031

Figure 53: Latin America Influenza Vaccine Market Value Share Analysis, by Type, 2022 and 2031

Figure 54: Latin America Influenza Vaccine Market Attractiveness Analysis, by Type, 2023-2031

Figure 55: Latin America Influenza Vaccine Market Value Share Analysis, by Age Group, 2022 and 2031

Figure 56: Latin America Influenza Vaccine Market Attractiveness Analysis, by Age Group, 2023-2031

Figure 57: Latin America Influenza Vaccine Market Value Share Analysis, by Valency, 2022 and 2031

Figure 58: Latin America Influenza Vaccine Market Attractiveness Analysis, by Valency, 2023-2031

Figure 59: Latin America Influenza Vaccine Market Value Share Analysis, by Distribution Channel, 2022 and 2031

Figure 60: Latin America Influenza Vaccine Market Attractiveness Analysis, by Distribution Channel, 2023-2031

Figure 61: Middle East & Africa Influenza Vaccine Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017-2031

Figure 62: Middle East & Africa Influenza Vaccine Market Value Share Analysis, by Country/Sub-region, 2022 and 2031

Figure 63: Middle East & Africa Influenza Vaccine Market Attractiveness Analysis, by Country/Sub-region, 2023-2031

Figure 64: Middle East & Africa Influenza Vaccine Market Value Share Analysis, by Type, 2022 and 2031

Figure 65: Middle East & Africa Influenza Vaccine Market Attractiveness Analysis, by Type, 2023-2031

Figure 66: Middle East & Africa Influenza Vaccine Market Value Share Analysis, by Age Group, 2022 and 2031

Figure 67: Middle East & Africa Influenza Vaccine Market Attractiveness Analysis, by Age Group, 2023-2031

Figure 68: Middle East & Africa Influenza Vaccine Market Value Share Analysis, by Valency, 2022 and 2031

Figure 69: Middle East & Africa Influenza Vaccine Market Attractiveness Analysis, by Valency, 2023-2031

Figure 70: Middle East & Africa Influenza Vaccine Market Value Share Analysis, by Distribution Channel, 2022 and 2031

Figure 71: Middle East & Africa Influenza Vaccine Market Attractiveness Analysis, by Distribution Channel, 2023-2031

Figure 72: Global Influenza Vaccine Market Share Analysis, by Company, 2022

Copyright © Transparency Market Research, Inc. All Rights reserved